Together, they are launching a groundbreaking product aimed at improving health prediction and actuarial technology.
The core of this partnership is the introduction of Lorisco Life’s new tool, the PREADISAN risk score. The novel assessment method provides highly individualised insights, going beyond the traditional, statistics-based life expectancy models. By combining blood-based proteomic biomarker analysis with clinically driven AI models, PREADISAN delivers a cutting-edge approach to assessing mortality risks. The tool is the first of its kind, integrating biological data with long-term mortality risk assessment.
Howard Sams, CEO of Lorisco Life, highlighted the innovation behind this partnership. “We are proud to be partnering with Abacus Life to customise health predictions for end users through proteomics and machine learning. The PREADISAN risk score enables the Abacus team to offer an unprecedented level of tailored solutions for their clients.”
The collaboration marks a significant advancement in how health predictions and longevity planning can be integrated into financial and insurance services, setting a new standard for personalised health insights in the industry.
Abacus Life Chairman and CEO, Jay Jackson, echoed these sentiments. “We are excited to provide a more personalised approach to longevity and actuarial technology for our partners and clients.”
He added “PREADISAN forecasts will enhance our ability to focus on longevity and health in the future of financial planning and life settlements.”
